Literature DB >> 12789291

Death receptors and melanoma resistance to apoptosis.

Vladimir N Ivanov1, Anindita Bhoumik, Ze'ev Ronai.   

Abstract

Impaired ability to undergo programmed cell death in response to a wide range of external stimuli acquires melanomas a selective advantage for progression and metastasis as well as their notorious resistance to therapy. Better understanding of mechanisms that govern apoptosis has enabled identification of diverse routes by which melanomas manage to escape stimuli of apoptosis. Changes at genomic, transcriptional and post-translational levels of G-proteins and protein kinases (Ras, B-Raf) and their transcription factor effectors (c-Jun, ATF2, Stat3 and NF-kappaB) affects TNF, Fas and TRAIL receptors, which play important roles in acquiring melanoma's resistance to apoptosis. Here, we summarize our current understanding of changes that alters the regulation of death receptors during melanoma development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12789291     DOI: 10.1038/sj.onc.1206456

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

1.  Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Authors:  Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.

Authors:  Henrike Westekemper; Michael Freistuehler; Norbert Bornfeld; Klaus-Peter Steuhl; Max Scheulen; Ralf A Hilger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-11       Impact factor: 3.117

3.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

4.  Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas.

Authors:  Gwendoline Van Goietsenoven; Jenna Hutton; Jean-Paul Becker; Benjamin Lallemand; Francis Robert; Florence Lefranc; Christine Pirker; Guy Vandenbussche; Pierre Van Antwerpen; Antonio Evidente; Walter Berger; Martine Prévost; Jerry Pelletier; Robert Kiss; Terri Goss Kinzy; Alexander Kornienko; Véronique Mathieu
Journal:  FASEB J       Date:  2010-07-19       Impact factor: 5.191

5.  A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.

Authors:  Karl D Lewis; John A Thompson; Jeffrey S Weber; William A Robinson; Steven O'Day; Jose Lutzky; Sewa S Legha; Simon Floret; Francis Ruvuna; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

6.  The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.

Authors:  Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor
Journal:  J Transl Med       Date:  2007-01-26       Impact factor: 5.531

Review 7.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

8.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue.

Authors:  Liang-Liang Yu; Hong-Gang Yu; Jie-Ping Yu; He-Sheng Luo; Xi-Ming Xu; Jun-Hua Li
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

9.  One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.

Authors:  Dirk J Grünhagen; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

10.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.

Authors:  Anfernee Kai-Wing Tse; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.